For Immediate Release

ASX Announcement

1 September, 2026
Melbourne, Australia

CSL Enters Agreements with U.S. on Drug Prices and Manufacturing

CSL Limited (ASX:CSL; USOTC:CSLLY) today announces it has entered into agreements with the U.S. Administration to lower the cost of medicines in the United States and reflect the company's previously announced plans to expand its U.S. plasma production capacity.

An agreement has been entered into with the U.S. Department of Health and Human Services under which CSL will provide the U.S. Medicaid program with access to CSL medicines at prices comparable to those available in other developed countries. CSL has also agreed to similarly price any newly launched therapies for all payers in the U.S.

CSL has also signed an Onshoring Agreement with the U.S. Department of Commerce reflecting the company's plans to expand its manufacturing presence in Kankakee, Illinois. The $1.5 billion expansion, announced in March 2026, will increase CSL's capacity to produce plasma-derived therapies and reinforces its commitment to advancing manufacturing and economic growth in the United States.

CSL does not anticipate any material financial impact in FY27 from these agreements, which provide it with greater certainty regarding exposure to U.S. drug pricing and certain Section 232 tariffs.

Authorised for lodgement by:

Fiona Mead
Company Secretary

Investor Relations

Michelle Rees
P: +61 410 600 745
E: michelle.rees@csl.com.au

Media Relations

Brett Foley
P: +61 461 464 708
E: brett.foley@csl.com.au

CSL Limited | ABN 99 051 588 348 | 655 Elizabeth Street, Melbourne VIC 3000